{"id":828709,"date":"2025-03-24T03:33:07","date_gmt":"2025-03-24T07:33:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/"},"modified":"2025-03-24T03:33:07","modified_gmt":"2025-03-24T07:33:07","slug":"abivax-announces-full-year-2024-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/","title":{"rendered":"Abivax Announces Full Year 2024 Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>Abivax Announces Full Year 2024 Financial Results <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>\u2022<\/em>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<em>Cash balance of <\/em><strong><em>EUR 144.2M<\/em><\/strong><em> as of December 31, 2024; cash runway into Q4 2025<\/em><\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <em>Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (\u201cUC\u201d) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025<\/em><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>PARIS, France \u2013 March 24, 2025 \u2013 8:30 AM CET \u2013 <\/strong>Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of December 31, 2024. The 2024 financial statements, approved by the Company\u2019s Board of Directors on March 20, 2025, have been audited by the Company\u2019s statutory auditors, and the financial reports will be filed with the French and U.S. securities regulatory authorities, respectively, on March 24, 2025.<\/p>\n<p align=\"justify\">\n        <strong>Marc de Garidel, CEO of Abivax, commented:<\/strong><br \/>\n        <em>\u201c2025 is set to be a transformational year for Abivax, marking a pivotal moment in our journey. We are very pleased with our achievements in 2024, demonstrating both strong financial discipline and significant clinical progress. Our cash position secures a projected financial runway into Q4 2025, supporting the full enrollment of ABTECT in Q2 2025 and the anticipated top-line results from the 8-week induction trials in Q3 2025, a major inflection point for Abivax.\u201d<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Financial Highlights<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Cash Position<\/strong>: The Company had a cash balance of <strong>EUR 144.2M<\/strong> as of December 31, 2024, providing a projected cash runway into <strong>Q4 2025<\/strong>.<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\"><strong>Operational Expenditures<\/strong>: R&amp;D expenses increased year-over-year, reflecting continued investments in the Phase 3 ABTECT clinical program and manufacturing scale-up.\n<\/li>\n<li style=\"text-align:justify\"><strong>Financial Outlook<\/strong>: The Company remains focused on disciplined financial management while advancing its clinical development pipeline and preparing for potential commercialization.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Upcoming Milestones<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Completion of <strong>Phase 3 ABTECT induction trials enrollment<\/strong> \u2013 Q2 2025\n<\/li>\n<li style=\"text-align:justify\">\n          <strong>Top-line results from induction trials<\/strong> \u2013 Q3 2025<\/p>\n<\/li>\n<li style=\"text-align:justify\">Completion of <strong>44-week maintenance trial<\/strong> \u2013 Q2 2026\n<\/li>\n<li style=\"text-align:justify\">\n          <strong>Top-line results from maintenance study<\/strong> \u2013 Q2 2026<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>2024 financial highlights (IFRS figures)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:547.65pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:316.07px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Income Statement<\/strong>\n          <\/td>\n<td style=\"width:79.94px;border-top: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:101.2px;border-top: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>FY 2024<\/strong>\n          <\/td>\n<td style=\"width:101.2px;border-top: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>FY 2023<\/strong>\n          <\/td>\n<td style=\"width:30.6px;border-top: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:101.2px;border-top: solid black 1pt;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Change<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:316.07px;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>in millions of euros<\/strong>\n          <\/td>\n<td style=\"width:79.94px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:30.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:101.2px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:316.07px;border-left: solid black 1pt;vertical-align: middle\">Total operating income<\/td>\n<td style=\"width:79.94px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">12.5<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">4.6<\/td>\n<td style=\"width:30.6px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">7.9<\/td>\n<\/tr>\n<tr>\n<td style=\"width:316.07px;border-left: solid black 1pt;vertical-align: middle\">Total operating expenses<\/td>\n<td style=\"width:79.94px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:30.6px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:316.07px;border-left: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <em>of which Research and Development costs<\/em>\n          <\/td>\n<td style=\"width:79.94px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">(146.5)<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">(103.2)<\/td>\n<td style=\"width:30.6px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(43.3)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:316.07px;border-left: solid black 1pt;vertical-align: middle\">\u00a0\u00a0\u00a0\u00a0\u00a0<em> of which Sales and Marketing costs<\/em><\/td>\n<td style=\"width:79.94px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">(6.0)<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">(6.4)<\/td>\n<td style=\"width:30.6px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0.4<\/td>\n<\/tr>\n<tr>\n<td style=\"width:316.07px;border-left: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <em> of which General and Administrative costs<\/em>\n          <\/td>\n<td style=\"width:79.94px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">(32.9)<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">(22.4)<\/td>\n<td style=\"width:30.6px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(10.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:316.07px;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Operating loss<\/strong>\n          <\/td>\n<td style=\"width:79.94px;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>(172.9)<\/strong>\n          <\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>(127.4)<\/strong>\n          <\/td>\n<td style=\"width:30.6px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:101.2px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>(45.5)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:316.07px;border-left: solid black 1pt;vertical-align: middle\">Financial loss<\/td>\n<td style=\"width:79.94px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">(3.3)<\/td>\n<td style=\"width:101.2px;text-align: center;vertical-align: middle;vertical-align: middle\">(20.4)<\/td>\n<td style=\"width:30.6px;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:101.2px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">17.1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:316.07px;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Net loss for the period<\/strong>\n          <\/td>\n<td style=\"width:79.94px;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:101.2px;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>(176.2)<\/strong>\n          <\/td>\n<td style=\"width:101.2px;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>(147.8)<\/strong>\n          <\/td>\n<td style=\"width:30.6px;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:101.2px;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>(28.4)<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:549pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:293.4px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Balance Sheet<\/strong>\n          <\/td>\n<td style=\"width:31.74px;border-top: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;border-top: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>FY2024<\/strong>\n          <\/td>\n<td style=\"width:147.8px;border-top: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>FY2023<\/strong>\n          <\/td>\n<td style=\"width:26.6px;border-top: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-top: solid black 1pt;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Change<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">\n            <em>in millions of euros<\/em>\n          <\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:26.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:26.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Net financial position<\/strong>\n          <\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>53.4<\/strong>\n          <\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>203.2<\/strong>\n          <\/td>\n<td style=\"width:26.6px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>(149.7)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">of which other financial assets and other receivables and assets*<\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">23.2<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">28.3<\/td>\n<td style=\"width:26.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(5.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">of which fixed-term deposits (maturing in &gt; 1 year)<\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">0.0<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">0.0<\/td>\n<td style=\"width:26.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">0.0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">of which fixed-term deposits (maturing in &lt; 1 year)<\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">0.0<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">9.0<\/td>\n<td style=\"width:26.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(9.0)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">of which available cash and cash equivalents<\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">144.2<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">251.9<\/td>\n<td style=\"width:26.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(107.7)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">(of which financial liabilities)**<\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">(114.0)<\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">(77.0)<\/td>\n<td style=\"width:26.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(37)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Total Assets<\/strong>\n          <\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>205.2<\/strong>\n          <\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>327.1<\/strong>\n          <\/td>\n<td style=\"width:26.6px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>(121.9)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:147.8px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:26.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:293.4px;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Total Shareholders\u2019 Equity<\/strong>\n          <\/td>\n<td style=\"width:31.74px;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>40.6<\/strong>\n          <\/td>\n<td style=\"width:147.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>196.0<\/strong>\n          <\/td>\n<td style=\"width:26.6px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:84.67px;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>(155.4)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"6\" style=\"width:732px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">* Excluding items of the liquidity contract (liquidity and own shares) and prepaid expenses<br \/>** Financial liabilities include borrowings, convertible loan notes, derivative instruments, royalty certificates and other financial liabilities<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Operating income increased by EUR 7.9M to EUR 12.5M in 2024 compared to EUR 4.6M from 2023. The increase was primarily driven by the following:\n<ul type=\"circle\">\n<li style=\"text-align:justify\">EUR 2.2M of additional Research Tax Credits, out of which EUR 1.0M related to the 2021 tax year and the remaining amount related to the 2024 tax year. The increase in the 2024 tax credits was due to the net reimbursements of conditional advances made to Bpifrance in relation to the RNP-VIR and CARENA projects, following the termination of both projects.<\/li>\n<li style=\"text-align:justify\">Subsidies increased by a non-cash amount of EUR 4.1M, which was recognized following the termination of the RNP-VIR and CARENA conditional advances granted by Bpifrance. In connection with the termination, Bpifrance agreed to waive 60% of the remaining conditional advances and accrued interests.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Research and development (R&amp;D) expenses increased by EUR 43.3M to EUR -146.5M in 2024 compared to EUR\u00a0-103.2M in 2023. This increase was predominantly driven by increase in expenses related to:\n<ul type=\"circle\">\n<li style=\"text-align:justify\">Our UC clinical program, driven by the progression of Phase 3 clinical trials for obefazimod in UC;<\/li>\n<li style=\"text-align:justify\">A EUR 4.6M increase in expenses related to our Crohn\u2019s disease (CD) clinical program, driven by planning costs incurred for and progression of the Phase 2b CD trial; and<\/li>\n<li style=\"text-align:justify\">A EUR 8.2M, or 76%, increase related to the overall expansion of the research and development headcount to support our organizational growth and the issuance of new equity awards to officers and employees in research and development.\n<\/li>\n<\/ul>\n<\/li>\n<li style=\"text-align:justify\">Sales and marketing (S&amp;M) expenses remained relatively consistent between 2024 and 2023.\n<\/li>\n<li style=\"text-align:justify\">General and administrative (G&amp;A) expenses increased by EUR 10.5M to -32.9M compared to EUR\u00a0-22.4M for 2023. This increase was primarily driven by the full year impact of the build out of our G&amp;A organization (increased headcount and equity-based compensation costs) which started in late 2023 to support the expansion of the Company, as well as increased legal and professional fees and other costs associated with operating as a dual-listed public company.\n<\/li>\n<li style=\"text-align:justify\">Total number of employees as of December 31, 2024 was 69 compared to 61 as of December 31, 2023.\n<\/li>\n<li style=\"text-align:justify\">For the year ended December 31, 2024, the Company\u2019s EUR -3.3M net financial loss was driven primarily by the following items:\n<ul type=\"circle\">\n<li style=\"text-align:justify\">Interest expenses of EUR -11.6M relating to borrowings and loans;<\/li>\n<li style=\"text-align:justify\">Non-cash expense of EUR -0.8M in relation to the fair value of the Company\u2019s royalty certificates;<\/li>\n<li style=\"text-align:justify\">Non-cash expense of EUR -1.4M in relation to an increase in the fair value of the Heights convertible notes;<\/li>\n<li style=\"text-align:justify\">Non-cash expense of EUR -1.5M in relation to an increase in the fair value of the Kreos \/ Claret share warrants (\u201cBSA\u201d); and<\/li>\n<li style=\"text-align:justify\">Transaction costs amounting to EUR 1.6M in connection with the drawdowns of Tranches B and C of the Kreos\/Claret financing;<\/li>\n<li style=\"text-align:justify\">Partially offset by interest income of EUR 8.2M in relation to the invested proceeds from the Company\u2019s U.S. initial public offering and listing on Nasdaq and concurrent global private offering, and foreign exchange gains of EUR 2.8M (EUR 1.7M non-cash impact of the revaluation of U.S. dollar-denominated cash and cash equivalents as of December 31, 2024).\n<\/li>\n<\/ul>\n<\/li>\n<li style=\"text-align:justify\">Cash position as of December 31, 2024, was EUR\u00a0144.2, compared to EUR 261.0 (including other financial assets of EUR 9.0M) as of December 31, 2023. The decrease was driven by:\n<ul type=\"circle\">\n<li style=\"text-align:justify\">EUR 154.1M being used in operating activities to advance the Phase 3 clinical trials of obefazimod in UC and the initiation of the Phase 2b trial for CD, and the full year impact of increased legal and professional fees and other infrastructure costs associated with operating as a dual-listed public company and changes in working capital; and<\/li>\n<li style=\"text-align:justify\">Debt and interest repayments of EUR 20.9M;<\/li>\n<li style=\"text-align:justify\">Partially offset by drawdowns on Tranches B and C of the Kreos\/Claret Financing of EUR 50.0M.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\">Based on the currently available funds and the expected reimbursement of the research tax credits (CIR) from 2024 in the second half of 2025 amounting to EUR 5.7M, Abivax expects to be able to finance its operating cash flow requirements into Q4 2025.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <br \/>About Abivax<\/strong>\n      <\/p>\n<p align=\"justify\">Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax\u2019s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <br \/>Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Patrick Malloy<br \/>SVP, Investor Relations <br \/>Abivax SA<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JXjHFBU2rsbfIyIakuzuEx1vqUaYZmCQnaQA2dsJ4AwE_rgUJnk-ErsljDFYOGblxjLweQaJ-kMPO6r0JvcNMtzWcCh1V0bWSTRrFmJOUcF9-IyFSxoY3IBSO7P_Bvto\" rel=\"nofollow\" target=\"_blank\">patrick.malloy@abivax.com<\/a><br \/>+1 847 987 4878<\/p>\n<p align=\"justify\">\n        <br \/>\n        <strong>FORWARD-LOOKING STATEMENTS <\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company\u2019s business and financial objectives. Words such as \u201cdesign,\u201d \u201cexpect,\u201d \u201cforward,\u201d \u201cfuture,\u201d \u201cpotential,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cwill\u201d and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning or implying the therapeutic potential of Abivax&#8217;s drug candidates, Abivax\u2019s expectations regarding the availability of data and timing of reporting results from its clinical trials, including its Phase 3 ABTECT-1 and ABTECT-2 induction trials and Phase 3 ABTECT maintenance trial, enrollment of patients in clinical trials, Abivax\u2019s cash runway, and other statements that are not historical fact. Although Abivax\u2019s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorit\u00e9 des March\u00e9s Financiers pursuant to its legal obligations including its universal registration document (Document d\u2019Enregistrement Universel) and in the Company\u2019s Annual Report on Form 20-F for the fiscal year ended December 31, 2024 to be filed with the\u00a0U.S. Securities and Exchange Commission\u00a0under the caption \u201cRisk Factors.\u201d These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the Company and regulatory agencies and IRBs\/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NDgwZWU4YjQtNDQxMy00YjA0LWJiYmUtYTkzYzYyNTMwZmI1LTEwMzE2ODktMjAyNS0wMy0yNC1lbg==\/tiny\/Abivax.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abivax Announces Full Year 2024 Financial Results \u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (\u201cUC\u201d) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France \u2013 March 24, 2025 \u2013 8:30 AM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of December 31, 2024. The 2024 financial statements, approved by the Company\u2019s Board of Directors on March 20, 2025, have &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Abivax Announces Full Year 2024 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828709","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abivax Announces Full Year 2024 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abivax Announces Full Year 2024 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Abivax Announces Full Year 2024 Financial Results \u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (\u201cUC\u201d) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France \u2013 March 24, 2025 \u2013 8:30 AM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of December 31, 2024. The 2024 financial statements, approved by the Company\u2019s Board of Directors on March 20, 2025, have &hellip; Continue reading &quot;Abivax Announces Full Year 2024 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T07:33:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abivax Announces Full Year 2024 Financial Results\",\"datePublished\":\"2025-03-24T07:33:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/\"},\"wordCount\":1717,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/\",\"name\":\"Abivax Announces Full Year 2024 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==\",\"datePublished\":\"2025-03-24T07:33:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-full-year-2024-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abivax Announces Full Year 2024 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abivax Announces Full Year 2024 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Abivax Announces Full Year 2024 Financial Results - Market Newsdesk","og_description":"Abivax Announces Full Year 2024 Financial Results \u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (\u201cUC\u201d) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France \u2013 March 24, 2025 \u2013 8:30 AM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of December 31, 2024. The 2024 financial statements, approved by the Company\u2019s Board of Directors on March 20, 2025, have &hellip; Continue reading \"Abivax Announces Full Year 2024 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-24T07:33:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abivax Announces Full Year 2024 Financial Results","datePublished":"2025-03-24T07:33:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/"},"wordCount":1717,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/","name":"Abivax Announces Full Year 2024 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==","datePublished":"2025-03-24T07:33:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTUyMCM0MDIxMDA2MTYjMjAyMDExNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-full-year-2024-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abivax Announces Full Year 2024 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828709"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828709\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}